America First Investment Advisors LLC Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

America First Investment Advisors LLC trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 53,300 shares of the medical research company’s stock after selling 2,422 shares during the quarter. Thermo Fisher Scientific makes up about 5.6% of America First Investment Advisors LLC’s holdings, making the stock its 4th largest position. America First Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $30,885,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in TMO. Wellington Management Group LLP lifted its position in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after purchasing an additional 1,270,191 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Thermo Fisher Scientific by 54.7% in the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares in the last quarter. Franklin Resources Inc. grew its stake in Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC grew its stake in Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock valued at $720,576,000 after acquiring an additional 825,649 shares in the last quarter. Finally, Capital World Investors grew its stake in Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock valued at $4,988,132,000 after acquiring an additional 706,572 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $448.55 on Tuesday. The firm’s 50-day moving average price is $479.71 and its 200-day moving average price is $537.15. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a market cap of $166.69 billion, a PE ratio of 24.66, a PEG ratio of 1.98 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TMO shares. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. UBS Group restated a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Citigroup lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, Morgan Stanley reissued an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $616.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.